Regulatory Approval

Tigo Energy's certified solar-plus-storage solution enters Romania, poised to accelerate the nation's rapid green energy transition for homeowners.

With a rare SRO license and CEO experience, Kym Harshaw's move to ZettaJoule signals a serious push to commercialize advanced high-temperature reactors.

With regulatory hurdles cleared, Mid Penn's acquisition of 1st Colonial awaits a final shareholder vote, set to reshape banking in the Philly region.

DraftKings partners with Crypto.com to launch player-specific sports contracts and eyes political markets, navigating a complex federal regulatory landscape.

American Battery Technology Co. reports record revenue and a crucial cash flow turning point, accelerating its plans for domestic mineral recycling and mining.

Republic Technologies taps Canadian Solar’s CFO, signaling a strategic move to blend traditional financial discipline with Web3 infrastructure development.

With a massive Bitcoin injection, TIRX aims for stablecoin dominance in ASEAN, but faces a maze of regulatory hurdles and unproven technical claims.

New clinical data reveals a minimally invasive spine implant significantly cuts pain, improves function, and reduces opioid use for SI joint dysfunction.

The cybersecurity leader's new DSPM capabilities aim to solve the AI data dilemma, promising to protect the entire AI innovation lifecycle.

South Korean firm Neurophet wins its third FDA clearance for an AI tool that precisely tracks Alzheimer's therapy side effects, eyeing U.S. expansion.

Australian biotech Immutep reaches a key milestone in its Phase III trial for a novel lung cancer therapy, a major step in a multi-billion dollar market.

Crypto exchange Phemex now offers 24/7 stock and metal futures, a bold move to unify markets that also navigates a complex and risky regulatory maze.

Delonix Bioworks' next-gen meningitis B vaccine, DX-104, is cleared for human trials in China and Australia, aiming to challenge the market leaders.

Marex's acquisition of Webb Traders signals a major push into automated equity derivatives, aiming to internalize hedging and challenge market norms.

The fintech firm is pivoting hard into digital assets, planning to mine Bitcoin Cash while launching a novel crypto life insurance business in Bermuda.

Aucta Pharma launches two rare disease drugs, PYQUVI and ZELVYSIA, betting on a 'branded-generic' model to navigate highly competitive markets.

A new 7,500-participant study will test a cfDNA-based screen to identify high-risk pregnancies months before symptoms appear, a potential paradigm shift.

Mawson Infrastructure reports a steep Q4 revenue drop but a smaller annual loss, clearing major legal hurdles to focus on its AI and green energy future.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

Kelun-Biotech's sac-TMT gains its fourth approval in China, doubling survival time for patients with advanced HR+/HER2- breast cancer.